Keith A. Moskowitz joins Cellphire as Vice President for Discovery

May 1, 2018 -- Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that Keith A. Moskowitz, Ph.D. MPM, has joined the company as Vice President of Discovery.  Dr. Moskowitz has more than two decades of leadership experience directing R&D, liaison and strategy in companies with revenues in excess of $1 billion. 

Dr. Moskowitz has spent 20 years in technical, management and liaison positions in the areas of hemostasis and thrombosis, infectious and genetic diseases in a variety of medical industries, including laboratory and POC diagnostics, medical devices, biologicals and custom laboratory services. He has a thorough understanding of both domestic and international regulatory and distribution channels, OEM, government grants and contracts, cGMP and GLP and has taken several products from idea to market. He is the author of over four dozen peer reviewed publications, abstracts and patents and is a member of the American Society of Hematology, The American Society of Clinical Chemistry, The International Society for Hemostasis and Thrombosis and the American Academy of Project Management, The American Association for Clinical Chemistry and the American Association of Clinical Pathologists. 

“We at Cellphire are thrilled to have Keith Moskowitz join our R&D team,” said Cellphire CEO Stephen Willard. “Keith brings a deep understanding and expertise in hemostasis, and we look forward to working with him to push our platform cell stabilization technology into new and exciting areas.”

Among his significant previous positions, Dr. Moskowitz served as Vice President of Technology and Development at PTS Diagnostics, Vice President of Product Development & Medical Science Liaison at TraumaCure, VP of Product Development at BioMarker Strategies and Director of Corporate Product Development at SeraCare Life Sciences, where he was also Director of manufacturing for its MD facilities and for custom laboratory services. He was Director of Hematology and R&D at Adlyfe, and Accumetrics where he was directly responsible for the development of the VerifyNow Rapid Platelet Function Assay. 

Dr. Moskowitz holds a Bachelor of Science degree from Rutgers University, a Ph.D. – Biochemistry (PhD) degree from Temple University School of Medicine, was a post-doctoral fellow at the Mount Sinai Medical Center and is recognized as a Master Project Manager (MPM) by the American Academy of Project Management. 

# # # 

About Cellphire, Inc. 

Cellphire, Inc., based in Rockville, Maryland, is the only U.S. company developing freeze-dried platelet products. Cellphire is focused on applying its cellular stabilization technology to all cell types in order to provide lifesaving products where none are routinely available. Platelets are critical to the body’s vascular system and responsible for the body’s ability to stop bleeding. Unlike other blood products that can be frozen and stockpiled for use when needed, platelet products currently used can only be stored for 5-7 days. Cellphire’s lead product, Thrombosomes®, a human platelet derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a product that can be stored for years, then reconstituted with sterilized water. Cellphire’s platform technology has potential applications across a wide range of cell types and medical applications from trauma to wound care, imaging, targeted drug delivery and regenerative medicine.  This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021C.  For more information, please view


Cautionary Note Regarding Forward-Looking Statements  

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



Thomas Dann
(240) 268-2489 

Source:  Cellphire, Inc.